BioSpace News Archive

Alzheimer’s disease

In Novo’s GLP-1 Failure, Alzheimer’s Space Spies a Combination Opportunity

Despite the definitive failure of Novo Nordisk’s semaglutide in Alzheimer’s, biotech executives, analysts and other industry experts see potential in more testing of GLP-1s for the neurodegenerative disease, particularly in a combination approach.

January 2, 2026
·
5 min read
·
Annalee Armstrong
Mergers & acquisitions

Five Biggest Biopharma Takeovers of 2025

Four of this year’s biggest acquisitions topped 11-figure figures. One was 2025’s messiest bidding war.

January 2, 2026
·
8 min read
·
Tristan Manalac
Complete response letters

FDA Rejects Corcept and Outlook Filings, Crushing Stock Prices

Both companies received agency requests for more evidence of the effectiveness of their therapies.

January 2, 2026
·
2 min read
·
Nick Paul Taylor
Drug pricing

Pfizer Leads Industry-Wide Surge in Drug Prices for 2026 Despite Political Pressure

More than a dozen pharmas have recently struck deals with the White House to lower drug prices. Nevertheless, drugmakers reportedly plan to raise the U.S. prices of at least 350 branded medications.

January 2, 2026
·
2 min read
·
Nick Paul Taylor
Approvals

Vanda Ends 40-Year Motion Sickness Drug Drought With FDA Approval for Nereus

Jefferies analysts envision a steady launch curve that could ultimately drive meaningful sales from people who are dissatisfied with existing treatments.

January 2, 2026
·
3 min read
·
Nick Paul Taylor
$X ray of arm fracture with red pain point. Broken hand with open type of fracture. Human skeleton anatomy concept. Medical banner for clinic or hospital. Vector$

Phase III

Ultragenyx Loses $1B in Market Value as Bone Drug Fails To Reduce Fractures

With a pair of Phase III trial flops, Ultragenyx will explore cost reductions as analysts turn attention to an upcoming Angelman syndrome readout.

January 2, 2026
·
2 min read
·
Annalee Armstrong
Mergers & acquisitions

Big Pharma Dealmakers Joined by Spunky Group of Biotech Buyers in Q4

While Novartis secured the biggest deal of the fourth quarter, a handful of riveting tales emerged from the bottom of the M&A list, including a zombie buyout and a bidding war. And no, we’re not talking about Metsera.

January 2, 2026
·
2 min read
·
Annalee Armstrong
Depression

Biohaven Notches Another Psychiatric Failure Months After Key FDA Rejection

The major depressive disorder failure for BHV-7000 is the drug’s second, after Biohaven’s spinocerebellar ataxia treatment troriluzole was rejected by the FDA in November 2025.

January 2, 2026
·
1 min read
·
Annalee Armstrong
ChemPartner Unveils Updated Visual Identity and Digital Experience Reflecting Its Reputation as a Trusted Biopharma Partner

January 2, 2026
·
2 min read
Press Releases

AINGENS MACg Slide Generator

January 2, 2026
·
1 min read